Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting
from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose …

Purpose To provide evidence-based guidance on the optimum prevention and treatment
approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing
impact as oncological treatments, using potentially neurotoxic chemotherapy, improve …

This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …

Chemotherapy induced peripheral neuropathy (CIPN) is a potentially dose limiting side
effect of commonly used chemotherapeutic agents like taxanes, vinca-alkaloids, platinum …

Background The objective of this study was to systematically review all available literature
concerning chemotherapy-induced peripheral neuropathy (CIPN) and quality of life (QOL) …

Purpose To gain insight into the prevalence and severity of chemotherapy-induced
neuropathy and its influence on health-related quality of life (HRQOL) in a population-based …

Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …

Background There are inconsistencies in the literature regarding the prevalence and
assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored …